Clinical Trials

Breast Neoplasms

NCT06133517 2026-03-16

PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer

70 enrolled

Urothelial Bladder Carcinoma

NCT05833867 2026-03-13

Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer

Phase 1 Recruiting

Localized Muscle Invasive Bladder Urothelial Carcinoma

NCT05884320 2026-03-11

Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers

30 enrolled

Head & Neck

Salivary Gland Neoplasms

NCT06028932 2026-03-05

A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients

Ovarian Neoplasms

NCT04468061 2026-02-27

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

110 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05581589 2026-02-27

Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer

18 enrolled

Urinary Bladder Neoplasms

NCT06100874 2026-02-24

A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)

28 enrolled

Breast Neoplasms

NCT06178588 2026-02-24

Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma

15 enrolled

Gastrointestinal

Cholangiocarcinoma, Klatskin Tumor

NCT07063212 2026-02-19

A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)

40 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT04251416 2026-02-17

A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma

50 enrolled

Endometrial Neoplasms

NCT06963905 2026-02-17

SIMONE

60 enrolled

Triple Negative Breast Neoplasms

NCT05838521 2026-02-06

A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer

Uterine Cervical Neoplasms

NCT07339059 2026-01-30

SG and Immunotherapy as Maintenance Therapy for Extensive-stage Small-cell Lung Cancer

35 enrolled

Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

NCT07367178 2026-01-28

SATROPIN

30 enrolled

Breast Neoplasms

NCT07368543 2026-01-28

STORM

216 enrolled

Phase 2 Enrolling by invitation

Breast Neoplasms

NCT07359404 2026-01-22

Sacituzumab Govitecan Plus Bevacizumab in Metastatic TNBC

60 enrolled

Advanced Breast Cancer

NCT04448886 2026-01-15

Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC

110 enrolled 26 charts

Breast Neoplasms

NCT06263543 2025-12-26

SERIES

75 enrolled

Breast Neoplasms

NCT06065371 2025-12-19

Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy

Phase 1 Recruiting

Phase 1/2 Active not recruiting

Gastrointestinal

Biliary Tract Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT04863885 2025-12-17

Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients

46 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06238921 2025-12-05

Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases

31 enrolled

Phase 1/2 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06612203 2025-12-05

WIN-B

76 enrolled

Advanced Breast Cancer

NCT05520723 2025-12-04

PRIMED

Phase 2 Completed

50 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06409390 2025-12-04

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

15 enrolled

Breast Neoplasms

NCT06040970 2025-12-02

Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer

54 enrolled

Phase 3 Active not recruiting

Ovarian Neoplasms, Uterine Neoplasms

NCT04595565 2025-11-25

SASCIA

1,332 enrolled

Triple Negative Breast Neoplasms

NCT04986579 2025-11-19

Scalp Cooling in MBC

120 enrolled

Breast Neoplasms

NCT06081244 2025-11-19

ADAPT-TN-III

Phase 3 Recruiting

348 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04724018 2025-11-04

Sacituzumab Govitecan Plus EV in Metastatic UC

106 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05675579 2025-11-04

A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)

27 enrolled

Breast Neoplasms

NCT07011654 2025-10-23

Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)

31 enrolled

Triple Negative Breast Neoplasms

NCT04230109 2025-10-14

NeoSTAR

260 enrolled

Phase 1 Active not recruiting

Triple Negative Breast Neoplasms

NCT05143229 2025-10-06

ASSET

18 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT06462092 2025-09-29

Sacituzumab Govitecan and Intrathecal Chemotherapy for Treating Leptomeningeal Metastases From Her2-negative Breast Cancer

Phase 3 Not yet recruiting

34 enrolled

BreastCNS

Breast Neoplasms, Meningeal Carcinomatosis

NCT07178730 2025-09-17

ADAPT-TN-IV

765 enrolled

Phase 1 Not yet recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07163481 2025-09-16

SoGreat

12 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT06504719 2025-09-15

Safety and Efficacy Real-world Data of Trastuzumab Deruxtecan and Sacituzumab Govitecan

Completed

312 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms, Neoplasm Metastasis

NCT07040644 2025-09-08

A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC

150 enrolled

Triple Negative Breast Neoplasms

NCT07151586 2025-09-03

ALTER

260 enrolled

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT04434040 2025-08-19

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

40 enrolled

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT04559230 2025-08-05

Sacituzumab Govitecan in Recurrent Glioblastoma

32 enrolled

CNS

Glioblastoma

NCT06923826 2025-07-25

TROP2

32 enrolled

Head & Neck

Salivary Gland Neoplasms, Thyroid Neoplasms

NCT07046455 2025-07-01

Trop-2 Targeted PET Probes in Advanced TNBC

Phase NA Recruiting

Triple Negative Breast Neoplasms

NCT06665178 2025-06-25

Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast Cancer

Breast Neoplasms

NCT05552001 2025-06-11

ISIdE

Phase 3 Recruiting

96 enrolled

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT05226117 2025-06-03

Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder Cancer

44 enrolled

Carcinoma, Transitional Cell

NCT06991790 2025-05-28

Sacituzumab Govitecan + Toripalimab as First - Line Therapy for Advanced Triple - Negative Breast Cancer and Biomarker Exploration

Recruiting

51 enrolled

Triple Negative Breast Neoplasms

NCT06055465 2025-05-15

Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab in Resectable Non-Small Cell Lung Cancer

37 enrolled

Thoracic

Lung Neoplasms

NCT03725761 2025-05-13

Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy

31 enrolled 12 charts